Direct Coombs Test (DCT) Antibody Market Report 2026

Direct Coombs Test (DCT) Antibody Market Overview

• Direct Coombs Test (DCT) Antibody market size has reached to $6.55 billion in 2025 • Expected to grow to $11.17 billion in 2030 at a compound annual growth rate (CAGR) of 11.2% • Growth Driver: Rising Demand For Personalized Medicine Fueling The Growth Of The Market Due To Precise Immune Profiling And Tailored Treatments • Market Trend: Advancing Transfusion Safety With Gel-Based Immunoassays • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Direct Coombs Test (DCT) Antibody Market?

A direct coombs test (DCT) antibody is an antibody that specifically targets the dopachrome tautomerase (DCT) protein, also known as tyrosinase-related protein 2 (TRP-2). This protein plays a key role in melanin biosynthesis and is often used as a marker for melanocyte differentiation and melanoma research. It is widely applied in detecting, quantifying, and studying DCT expression in biological samples. The main types of direct coombs test (DCT) antibody are monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and bispecific antibodies. Monoclonal antibodies refer to laboratory-produced molecules designed to bind specifically to antigens on red blood cells, enabling precise detection of immune-mediated hemolysis during diagnostic testing. The various sources include human, mouse, rabbit, other mammals, and recombinant sources and are utilized across various applications such as cancer treatment, autoimmune diseases, infectious diseases, transplant rejection, and other related uses. The key end-users include pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic and research institutes, and diagnostic laboratories.

What Is The Direct Coombs Test (DCT) Antibody Market Growth Forecast?

The direct coombs test (dct) antibody market size is expected to see rapid growth in the next few years. It will grow to $11.17 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to expansion of precision oncology research, increasing demand for next-generation antibody formats, rising investments in biologics manufacturing, growth of personalized medicine applications, advances in antibody discovery platforms. Major trends in the forecast period include increasing use of recombinant antibody technologies, growing demand for high-specificity monoclonal antibodies, expansion of antibody applications in oncology research, rising adoption of bispecific antibody formats, enhanced focus on scalable antibody production.

Global Direct Coombs Test (DCT) Antibody Market Segmentation

1) By Type: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, Bispecific Antibodies 2) By Source: Human, Mouse, Rabbit, Other Sources 3) By Application: Cancer Treatment, Autoimmune Diseases, Infectious Diseases, Transplant Rejection, Other Applications 4) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic And Research Institutes, Diagnostic Laboratories Subsegments: 1) By Monoclonal Antibodies: Mouse Monoclonal Antibodies, Rabbit Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies 2) By Polyclonal Antibodies: Rabbit Polyclonal Antibodies, Goat Polyclonal Antibodies, Sheep Polyclonal Antibodies, Chicken Polyclonal Antibodies, Donkey Polyclonal Antibodies 3) By Recombinant Antibodies: Mammalian Expression Recombinant Antibodies, Bacterial Expression Recombinant Antibodies, Yeast Expression Recombinant Antibodies, Insect Expression Recombinant Antibodies, Plant Expression Recombinant Antibodies 4) By Bispecific Antibodies: Immune Cell Engager Bispecific Antibodies, Dual Variable Domain Bispecific Antibodies, Cross Format Bispecific Antibodies, Knob And Hole Bispecific Antibodies, Fragment-Based Bispecific Antibodies

What Is The Driver Of The Direct Coombs Test (DCT) Antibody Market?

The rising demand for personalized medicine is expected to propel the growth of the direct coombs test (DCT) antibody market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Direct coombs test (DCT) antibody enhances personalized medicine by enabling precise detection of antibodies or complement bound to red blood cells. It helps identify immune-mediated hemolytic conditions, allowing clinicians to tailor treatments based on a patient’s specific immune profile, improving diagnostic accuracy and therapeutic outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the direct coombs test (DCT) antibody industry.

Key Players In The Global Direct Coombs Test (DCT) Antibody Market

Major companies operating in the direct coombs test (dct) antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bio-Rad Laboratories Inc., Fortress Diagnostics Limited, Lab-Care Diagnostics (India) Pvt. Ltd., SIFIN Diagnostics GmbH, Hemo Bioscience Inc., Rapid Labs Ltd, AnaMol Laboratories Pvt. Ltd., Jiangyin Libo Biotechnology Co. Ltd., MicroSidd India Pvt. Ltd., Atlas Medical GmbH, Lorne Laboratories Ltd, Sanquin Reagents B.V., BAG Diagnostics GmbH, CE-Immundiagnostika GmbH, Biolab Diagnostics (India) Pvt. Ltd., Singapore Biosciences Pte. Ltd.

Global Direct Coombs Test (DCT) Antibody Market Trends and Insights

Major companies operating in the direct coombs test (DCT) antibody market are focusing on developing technologically advanced solutions, such as gel-based immunoassays, to ensure reliability, enhance laboratory workflow, and maintain high standards in pre-transfusion testing. Gel-based immunoassays refer to a type of laboratory test in which antibodies and antigens interact within a gel matrix, allowing for visual detection of reactions such as agglutination. For instance, in October 2025, QuidelOrtho Corporation, a US-based in-vitro diagnostics company, received Food and Drug Administration (FDA) clearance for MTS DAT Card for gel-based direct antiglobulin testing on the ORTHO VISION platform. It features a ready-to-use card containing anti-IgG and anti-C3d monospecific reagents in the gel matrix of separate microtubes. This design allows for clear, objective, and simultaneous differentiation between IgG and complement sensitization, streamlining the investigation of immune-mediated hemolytic anemias and hemolytic disease of the fetus and newborn (HDFN). Its core purpose is to detect immunoglobulin G or complement bound to red blood cells, supporting hemolysis investigation and enhancing transfusion safety.

What Are Latest Mergers And Acquisitions In The Direct Coombs Test (DCT) Antibody Market?

In March 2023, Werfen Life Sciences S.A., a Spain-based in vitro diagnostics company, acquired Immucor Inc. for approximately $2.0 billion. With this acquisition, Werfen aims to strengthen its leadership in transfusion medicine by integrating Immucor’s immunohematology portfolio, enhancing automation, expanding global reach, and improving patient safety in hemolysis detection and transfusion management. Immucor Inc. is a US-based company specializing in Direct Coombs Test (DCT) antibody and immunohematology diagnostics.

Regional Outlook

North America was the largest region in the direct coombs test (DCT) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Direct Coombs Test (DCT) Antibody Market?

The direct coombs test (DCT) antibody consists of sales of primary antibodies, secondary antibodies, antibody kits, assay reagents, western blot reagents, enzyme-linked immunosorbent assay (ELISA) kits, immunohistochemistry kits, ready-to-use detection kit, anti- direct coombs test (DCT) (TRP-2), and rabbit monoclonal primary antibody. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Direct Coombs Test (DCT) Antibody Market Report 2026?

The direct coombs test (dct) antibody market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the direct coombs test (dct) antibody industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.